Browsing by Author Krzakowski, Maciej

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2010Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Studyvan Zandwijk, Nico; Allan, S; Baliko, Zoltan; Gridelli, C; Heigener, David; Krzakowski, Maciej; Reck, Martin; Rischin, D.; Concord Clinical School: ANZAC Research InstituteErlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study, Journal of Thoracic Oncology, vol.5, 10,pp 1616-1622
2012A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancervan Zandwijk, Nico; Au, J; Benner, R; Blasinska-Morawiec, M; et al, various; Jassem, J; Krzakowski, Maciej; Manegold, Christian; Serwatowski, P; Szczesna, A.; Tan, E; Zatloukal, P; Concord Clinical School: ANZAC Research InstituteA phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer, Annals of Oncology, vol.23, 1, 2012,pp 72-77
2012Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung CancerBoyer, Michael; Barrios, Carlos; Blackhall, Fiona; Bover, Isabel; et al, Various; Frank, Richard; Heo, Dae Seog; Krzakowski, Maciej; Park, Keunchil; Ramalingam, Suresh; Rosell, Rafael Costa; Talbot, Denis; Central Clinical School: MedicineRandomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.30, 27, 2012,pp 3337-3344